AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

 AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

Shots:

  • The P-III POSEIDON study involves assessing of Imfinzi + platinum-based CT or Imfinzi + Tremelimumab + CT vs CT as monothx as a 1L treatment in patients with non-squamous or squamous mNSCLC with all PD-L1 expression levels
  • The P-III POSEIDON study resulted in meeting its 1EPs & 2EPs i.e, improvement in final PFS analysis in patients treated with Imfinzi + SoC platinum-based CT & improvement in PFS in patients treated with triple regimen respectively
  • Imfinzi is a mAb targeting PD-L1, blocking the interaction of PD-L1 with PD-1 and CD80 with its anticipated additional 1EPs of OS data in 2020 while Tremelimumab is a mAb targeting the activity CTLA-4, contributing to T cell activation and boosting the immune response to cancer

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Hindustan Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post